PFIZER INC. for PFIZER INC.
A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 1st Quarter - Report (this page) | Apr 19, 2009 | $6,140,000 | Replaced |
| 1st Quarter - Report | Jul 27, 2009 | $5,340,000 | Replaced |
| 1st Quarter - Amendment | Oct 20, 2009 | $5,340,000 | Replaced |
| 1st Quarter - Amendment | Sep 21, 2010 | $5,860,000 | Yes |
What was lobbied
10 issue areas, each in the filer's own words, with who lobbied on it and where.
Trade (domestic/foreign) TRD
US- China Trade Dialogues (JCCT) - market access and IP issues Trans Pacific Partnership talks US - EU Dialogues (TEC) - market access and regulatory issues Japan Market Access and Regulatory Issues US-Korea Free Trade Agreement (no bills) US-Peru Free Trade Agreement (no bills) US-Columbia Free Trade Agreement (no bills) US-Panama Free Trade Agreement (no bills) Norway Patent issues (no bills) Poland market access (no bills) Russia permanent normal trade relations (no bills) Turkey Market Access (no bills) Free Trade Agreement Implementation Legislation (Peru, Columbia, Panama, Korea, Israel, Saudi Arabia) OECD Accession Saudi Arabia Patent Issues (no bills) South Africa Pricing & Patent Issues (no bills) Israel Patent Issues (no bills) Czech Republic Market Access Finland Patent Issues Taiwan - Market Access Issues (TIFA talks) APEC Life Sciences Innovation Forum Mexico IP and market access issues Brazil IP Thailand Compulsory Licensing India IP and market access issues Australian FTA Implementation Special 301 Reform Legislation Trade Enforcement Legislation
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOSEPH DAMOND | — |
| STEPHANIE HENNING | — |
| ANTHONY PRINCIPI | — |
Taxation/Internal Revenue Code TAX
HR 1, American Recovery and Reinvestment Act of 2009 - general corporate tax issues HR 198, Healthcare Tax Deduction Act of 2009 - general corporate tax issues HR 422, R&D tax credit extension and Enhancement - R&D tax credit R&D tax credit extension and Enhancement (Senate) - R&D tax credit Deferral
| Lobbyist | Covered position, as disclosed |
|---|---|
| KIMBERLY JANE PINTER | — |
| ANTHONY PRINCIPI | — |
| ANNE WILSON | — |
Health Issues HCR
Veterans Healthcare issues Electronic Prescribing Comparative Effectiveness Research Health Information Technology Follow-on Biologics S. 4 - Comprehensive Health reform Act (1/09) S. 45 - Health Liability Reduction Act (1/09) S. 301 - Physician Payments Sunshine Act (1/09) H.R. 15 - National Health Insurance Act (1/09) H.R. 193 - AmeriCare Act (1/09) S. 501 - Fair Prescription Drug Competition Act (3/09) H.R. 1 - The American Recovery and Reinvestment Act H.R. 1427 - Promoting Innovation and Access to Life-Saving Medicine Act HR 2, Children's Health Insurance Program Reauthorization Act of 2009 S. 726 - Promoting Innovation and Access to Life-Saving Medicine Act H.R. 1548 - Pathway for Biosimilars Act S.717 21st Century Cancer ALERT Act S. Con Res 13 - Budget Reconciliation H. Con Res 85 - Budget Reconciliation Health Reform Initiatives Health Information Technology Comparative Effectiveness Research Follow on Biologics
| Lobbyist | Covered position, as disclosed |
|---|---|
| MELISSA BISHOP-MURPHY New | — |
| CHRISTOPHER CAREY | — |
| JOHN PAUL HALLIWELL | — |
| DOLLY JUDGE | — |
| LOUIS A LAMARCA | — |
| ANTHONY PRINCIPI | — |
| MYRON KEITH TERRY | — |
| ANNE WILSON | — |
Consumer Issues/Safety/Products CSP
S.80, Pharmaceutic Market Access Act, 1/09 HR 91, Shipment of Prescription Drugs between the States and the Virgin Islands, 1/09 HR 163, The Prescription Drug Affordability Act, 1/09 S. 501, Fair prescription Drug Competition Act, 3/09 S. 767, Independent Drug Education and Outreach Act, 4/09 HR 573, Act to Prohibit the Marketing of Authorized Generic Drugs, 1/09 HR 1427, Promoting Innovation and Access to Life-Saving Medicines Act, 3/09 HR 1548, Pathway for Biosimilars Act, 3/09 HR 759, The Food, drug and Cosmetic Globalization Act, 1/09
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOHN PAUL HALLIWELL | — |
| DOLLY JUDGE | — |
| LOUIS A LAMARCA | — |
| ANTHONY PRINCIPI | — |
Medicare/Medicaid MMM
HR 684, The Medicare Prescription Drug Savings and Choice Act of 2009 S. 75, Generics First Act of 2009 (Part D) HR 574, Medicare Home Infusion Therapy Coverage Act of 2009 Medicare Prescription Drug Benefit Implementation - retain Medicaid Rebates - retain the general issues section Medicare Coverage Average Manufacturer Price Regulation
| Lobbyist | Covered position, as disclosed |
|---|---|
| CHRISTOPHER CAREY | — |
| DOLLY JUDGE | — |
| ANTHONY PRINCIPI | — |
| ANNE WILSON | — |
Budget/Appropriations BUD
S. Con Res 13 - Budget Reconciliation FY 10 H. Con Res 85 - Budget Reconciliation FY 10 Administration budget proposal, deferral and other international tax issues H.R. 1 - The American Recovery and Reinvestment Act 2009
| Lobbyist | Covered position, as disclosed |
|---|---|
| CHRISTOPHER CAREY | — |
| JOSEPH DAMOND | — |
| JOHN PAUL HALLIWELL | — |
| DOLLY JUDGE | — |
| KIMBERLY JANE PINTER | — |
| ANTHONY PRINCIPI | — |
| ANNE WILSON | — |
Environment/Superfund ENV
Environmental issues related to pharmaceutical manufacturing
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOHN PAUL HALLIWELL | — |
| LOUIS A LAMARCA | — |
| ANTHONY PRINCIPI | — |
Defense DEF
Smoking Cessation Coverage VA Drug Coverage
| Lobbyist | Covered position, as disclosed |
|---|---|
| CHRISTOPHER CAREY | — |
| JOHN PAUL HALLIWELL | — |
| LOUIS A LAMARCA | — |
| ANNE WILSON | — |
Copyright/Patent/Trademark CPT
S. 515, Patent Reform Act of 2009 S. 299, Expert Patent Courts Pilot Program Act, 1/09 S. 369, Preserve Access to Affordable Generics, 2/09 S. 515 Patent Reform Act, 3/09 S.610, Patent Reform Act, 3/09 HR 1260, Patent Reform Act, 3/09 HR 1706, Protecting Consumer Access to Generics Drug Act, 3/09 HR 1548, Pathway for Biosimilars Act
| Lobbyist | Covered position, as disclosed |
|---|---|
| CHRISTOPHER CAREY | — |
| JOSEPH DAMOND | — |
| JOHN PAUL HALLIWELL | — |
| DOLLY JUDGE | — |
| LOUIS A LAMARCA | — |
| ANTHONY PRINCIPI | — |
Agriculture AGR
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOHN PAUL HALLIWELL | — |
| DOLLY JUDGE | — |
| ANTHONY PRINCIPI | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.